Malta - English - Medicines Authority

elara pharmaservices europe 239 blanchardstown corporate park, ballycoolin, dublin, d15 kv21, ireland - hydrocortisone - tablet - hydrocortisone 10 mg - corticosteroids for systemic use

Malta - English - Medicines Authority

elara pharmaservices europe 239 blanchardstown corporate park, ballycoolin, dublin, d15 kv21, ireland - hydrocortisone - tablet - hydrocortisone 20 mg - corticosteroids for systemic use

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - hydrocortisone 20mg;   - tablet - 20 mg - active: hydrocortisone 20mg   excipient: lactose monohydrate magnesium stearate maize starch povidone purified talc

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - hydrocortisone 5mg;   - tablet - 5 mg - active: hydrocortisone 5mg   excipient: lactose monohydrate magnesium stearate maize starch povidone purified talc

New Zealand - English - Medsafe (Medicines Safety Authority)

noumed pharmaceuticals limited - hydrocortisone 1%{relative} (synthesis uses no animal materials);  ;   - topical cream - 1 % - active: hydrocortisone 1%{relative} (synthesis uses no animal materials)     excipient: cetomacrogol 1000 cetostearyl alcohol chlorocresol liquid paraffin purified water white soft paraffin

Ireland - English - HPRA (Health Products Regulatory Authority)

ovelle limited - hydrocortisone - cream - 1 percent weight/weight - corticosteroids, weak (group i); hydrocortisone

Ireland - English - HPRA (Health Products Regulatory Authority)

amdipharm limited - hydrocortisone - tablet - 10 milligram(s) - glucocorticoids; hydrocortisone

Ireland - English - HPRA (Health Products Regulatory Authority)

amdipharm limited - hydrocortisone - tablet - 20 milligram(s) - glucocorticoids; hydrocortisone

United States - English - NLM (National Library of Medicine)

carilion materials management - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 20 mg - hydrocortisone tablets are indicated in the following conditions. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic carditis pem

United States - English - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj), pramoxine hydrochloride (unii: 88ayb867l5) (pramoxine - unii:068x84e056) - hydrocortisone acetate 2.5 g in 100 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.